Pre-Operative PARPi and Irradiation (POPI) in Women with an Incomplete Response to Neo Adjuvant Chemotherapy (NAC) for Breast Cancer.

Study Overview

The purpose of this study is to determine the number of participants who can handle the treatment within specific safety parameters, determine the number of participants who can handle safely the maximum tolerated dose (MTD) (within 50-200 mg/BID dose range) when combining Veliparib and radiation, as well as to identify side effects and their intensity at different dosing levels.

Study Description

The purpose of this study is to identify the side effects, if any, when radiation and Veliparib are given together to treat women who still have cancer in their breast or under arm lymph nodes after being treated with pre-surgery chemotherapy.

Additional Information

Participants will not be paid for their participation.

  • IRB Number: 1503214668 (J11155)
  • Research Study Identifier: TX5475
  • Principal Investigator: Richard Zellars, MD

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at or by phone at (888) 264-0005.